Virtu Financial’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Virtu Financial’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,350	Closed	-$229K	–	2122
2023 Q2	$229K	Sell	6,350 -4,273	-40%	-$176K	0.02%	742
2023 Q1	$395K	Buy	+10,623	New	+$478K	0.04%	433
2022 Q4	–	Sell	-9,423	Closed	-$658K	–	2333
2022 Q3	$658K	Sell	9,423 -647	-6%	-$47.9K	0.06%	295
2022 Q2	$676K	Buy	+10,070	New	+$640K	0.06%	294
2021 Q3	–	Sell	-7,607	Closed	-$1.23M	–	2118
2021 Q2	$1.23M	Buy	+7,607	New	+$1.22M	0.12%	149
2021 Q1	–	Sell	-1,886	Closed	-$414K	–	2170
2020 Q4	$414K	Sell	1,886 -2,741	-59%	-$593K	0.04%	501
2020 Q3	$768K	Buy	+4,627	New	+$633K	0.13%	177
2019 Q4	–	Sell	-3,776	Closed	-$294K	–	1952
2019 Q3	$294K	Buy	+3,776	New	+$354K	0.02%	773
2019 Q2	–	Sell	-3,558	Closed	-$261K	–	1967
2019 Q1	$261K	Buy	+3,558	New	+$242K	0.01%	856

Other funds holding MRTX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtu Financial's MRTX Position: Q3 2023 in Review

Virtu Financial sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 6,350 shares — an estimated $229K sold.

Virtu Financial first reported a position in MRTX in Q1 2019 and held it in 9 quarters. The position peaked at $1.23M in Q2 2021. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Virtu Financial reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Virtu Financial sold 6,350 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $229K.
Virtu Financial first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 9 quarters.
Virtu Financial's Mirati Therapeutics, Inc. Common Stock position peaked at $1.23M in Q2 2021.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.